LSL Pharma Group Inc.
LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally. The company offers dietary supplements and vitamins in the tablet and capsule form; niche sterile ophthalmic products in the form of ointments and drops; and cosmetic, pharmaceutical, and natural health … Read more
LSL Pharma Group Inc. (LSL) - Total Liabilities
Latest total liabilities as of September 2025: CA$34.81 Million CAD
Based on the latest financial reports, LSL Pharma Group Inc. (LSL) has total liabilities worth CA$34.81 Million CAD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LSL Pharma Group Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how LSL Pharma Group Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LSL Pharma Group Inc. Competitors by Total Liabilities
The table below lists competitors of LSL Pharma Group Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NevGold Corp
OTCQX:NAUFF
|
USA | $5.42 Million |
|
Ymc Co. Ltd
KQ:155650
|
Korea | ₩54.56 Billion |
|
Yulho Co. Ltd
KQ:072770
|
Korea | ₩96.88 Billion |
|
IRCE S.p.A
STU:IRQ
|
Germany | €128.12 Million |
|
M&F Bancorp Inc
PINK:MFBP
|
USA | $374.46 Million |
|
MAGURO GROUP PUBLIC COMPANY LIMITED
BK:MAGURO
|
Thailand | ฿615.94 Million |
|
SJ Group Co. Ltd
KQ:306040
|
Korea | ₩96.06 Billion |
|
Marvipol S.A.
WAR:MVP
|
Poland | zł655.61 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down LSL Pharma Group Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LSL Pharma Group Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LSL Pharma Group Inc. (2020–2024)
The table below shows the annual total liabilities of LSL Pharma Group Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$28.62 Million | +28.65% |
| 2023-12-31 | CA$22.25 Million | +1.02% |
| 2022-12-31 | CA$22.02 Million | +22.90% |
| 2021-12-31 | CA$17.92 Million | +9.89% |
| 2020-12-31 | CA$16.31 Million | -- |